Phatak P, Burger A M
Department of Pharmacology and Experimental Therapeutics, and Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Br J Pharmacol. 2007 Dec;152(7):1003-11. doi: 10.1038/sj.bjp.0707374. Epub 2007 Jul 2.
Telomerase and telomeres are attractive targets for anticancer therapy. This is supported by the fact that the majority of human cancers express the enzyme telomerase which is essential to maintain their telomere length and thus, to ensure indefinite cell proliferation--a hallmark of cancer. Tumours have relatively shorter telomeres compared to normal cell types, opening the possibility that human cancers may be considerably more susceptible to killing by agents that inhibit telomere replication than normal cells. Advances in the understanding of the regulation of telomerase activity and the telomere structure, as well as the identification of telomerase and telomere associated binding proteins have opened new avenues for therapeutic intervention. Here, we review telomere and telomerase biology and the various approaches which have been developed to inhibit the telomere/telomerase complex over the past decade. They include inhibitors of the enzyme catalytic subunit and RNA component, agents that target telomeres, telomerase vaccines and drugs targeting binding proteins. The emerging role of telomerase in cancer stem cells and the implications for cancer therapy are also discussed.
端粒酶和端粒是抗癌治疗的诱人靶点。这一观点得到以下事实的支持:大多数人类癌症都表达端粒酶,而端粒酶对于维持端粒长度至关重要,从而确保细胞无限增殖——这是癌症的一个标志。与正常细胞类型相比,肿瘤的端粒相对较短,这使得人类癌症可能比正常细胞更容易受到抑制端粒复制的药物的杀伤。在端粒酶活性调控和端粒结构理解方面的进展,以及端粒酶和端粒相关结合蛋白的鉴定,为治疗干预开辟了新途径。在此,我们综述端粒和端粒酶生物学以及在过去十年中开发的抑制端粒/端粒酶复合物的各种方法。它们包括酶催化亚基和RNA组分的抑制剂、靶向端粒的药物、端粒酶疫苗以及靶向结合蛋白的药物。还讨论了端粒酶在癌症干细胞中的新作用及其对癌症治疗的影响。